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Background: Failure to early detect multidrug-resistant tuberculosis (MDR-TB) results
in treatment failure and poor clinical outcomes, and highlights the need to rapidly detect
resistance to rifampicin (RIF) and isoniazid (INH).
Methods: In Multi-Fluorescence quantitative Real-Time PCR (MF-qRT-PCR) assay, 10
probes labeled with four kinds of fluorophores were designed to detect the mutations in
regions of rpoB, katG, mabA-inhA, oxyR-ahpC, and rrs.
The efficiency of MF-qRT-PCR assay was tested using 261 bacterial isolates and 33
clinical sputum specimens. Among these samples, 227 Mycobacterium tuberculosis
isolates were analyzed using drug susceptibility testing (DST), DNA sequencing and
MF-qRT-PCR assay.
Results: Compared with DST, MF-qRT-PCR sensitivity and specificity for RIF-resistance
were 94.6 and 100%, respectively. And the detection sensitivity and specificity for
INH-resistance were 85.9 and 95.3%, respectively. Compared with DNA sequencing,
the sensitivity and specificity of our assay were 97.2 and 100% for RIF-resistance and
97.9 and 96.4% for INH-resistance. Compared with Phenotypic strain identification,
MF-qRT-PCR can distinguish 227 M. tuberculosis complexes (MTC) from 34
Non-tuberculous mycobacteria (NTM) isolates with 100% accuracy rate.
Conclusions: MF-qRT-PCR assay was an efficient, accurate, reliable, and
easy-operated method for detection of RIF and INH-resistance, and distinction of MTC
and NTM of clinical isolates.
Keywords: quantitative real-time PCR, Mycobacterium tuberculosis, drug resistance, rifampicin, isoniazid
INTRODUCTION
Worldwide prevalence, high misdiagnosis rate, high treatment cost, and serious side-effects of drug
made MDR-TB a critical problem for global public health (WHO, 2012). Therefore, rapid and
accurate assays for resistance to first line anti-TB drugs (RIF and INH being the most significant)
are decisive in choosing drugs when starting therapy.
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Conventional drug susceptibility testing (DST) is the current
“gold standard” for assessment of TB Drug Resistant. But failure
of rapid diagnosis of DST leads to rising mortality, secondary
resistance, and transmission of drug resistant-TB cases.
Alternatively, molecular assays provide faster turnover time
while maintaining high sensitivity and specificity. Quantitative
real-time polymerase chain reaction (qRT-PCR) is considered as
one of the most widely applied molecular assays for diagnosis
of drug resistant tuberculosis (Cuevas-Córdoba and Zenteno-
Cuevas, 2010). It can accurately discriminate single nucleotide
polymorphism (SNP) with low risk of contamination and had
the shortest turn-around time (TAT) so far. qRT-PCR assays
have been applied to the detection of RIF and INH resistances
(García de Viedma et al., 2002; van Doorn et al., 2003; Marín
et al., 2004; Helb et al., 2010) using at most two color
probes so far. Most of these assays only detected mutations in
segments of rpoB related to RIF and/or in segments of katG
and inhA related to INH resistances. And some similar assays
distinguished Mycobacterium tuberculosis complex (MTC) from
Non-tuberculous mycobacteria (NTM) at the same time (Wada
et al., 2004; Ramirez et al., 2010). Several commercial MTC/DST
diagnostic kits based on qRT-PCR assay have appeared and
obtained regulatory approval (WHO, 2012; Food and Drug
Administration, 2015) including Xpert MTB/RIF (Cepheid)
(Boehme et al., 2010), Fluorotype MDRTB (Hain Lifescience)
(Pierce et al., 2003; Rice et al., 2012), RealTime MDR TB (Abbott
Molecular) (Chen et al., 2015), BDProbeTec (Becton Dickinson)
(UNITAID, 2015) and MeltPro Drug-Resistant TB RIF, and
Drug-Resistant INH kits(Xiamen Zeesan Biotech) (Hu et al.,
2014). While most of these kits can be automated and high-
throughput detection of mutations, they still have shortcomings
such as high cost, limited detection sites.
In the present study, we designed an improved MF-qRT-
PCR assay that uses 10 probes for the detection of drug-
resistant mutations in the 81-bp hot-spot region of rpoB,
codon 315 of katG, −15 position in the promoter of mabA-
inhA, −6 ∼ −47 positions in the intergenic region of oxyR-
ahpC, and 451 ∼ 471 positions in rrs to distinguish MTC from
NTM simultaneously. We evaluated this assay using 261 bacterial
isolates and 33 sputum specimens from three cities (Shenzhen,
Wuhan, and Shanghai) in China, compared to DNA sequencing
and phenotypic DST results.
And we compared the advantages and disadvantages of MF-
qRT-PCR assay with other diagnosis methods in Discussion.
MATERIALS AND METHODS
Bacterial Isolates and Clinical Specimens
Two hundreds and sixty-one bacterial isolates of TB patients
were used in this study. Among these, 150 isolates (collected
at the Wuhan Medical Treatment Center from August 2009 to
March 2010) were routinely cultured with egg-based Löwenstein-
Jansen medium at 37◦C, 91 isolates (collected at the Shenzhen
Third People’s Hospital from January 2011 to November 2011)
and 20 isolates (collected at Shanghai Pulmonary Hospital) were
selected from the cultures grown in Bactec MGIT 960. Thirty-
three clinical sputum specimens of TB suspects were selected
randomly from Shenzhen Third People’s Hospital. H37Rv strain
was a gift from State Key Laboratory of Genetic Engineering,
Institute of Genetics, School of Life Science, Fudan University
and was served as the wild-type Mycobacterium tuberculosis
Complex (MTC) control.
DST, sequencing, and MF-qRT-PCR assay were performed on
all bacterial isolates. Clinical sputum specimens were divided
into two portions. One portion of each sputum sample was
cultured using Bactec MGIT 960. The other portion was treated
to perform MF-qRT-PCR, and was analyzed by TB quantitative
PCR kit (Qiagen, Germen).
MF-qRT-PCR
Sample Treatment and DNA Extraction
DNAs of culture isolates were re-suspended into 100 µl lysis
buffer which composed of 50 mmol/L Tris-HCl(Ph8.0), 2 mM
EDTA(Ph8.0),100 mmol/L NaCl, heated at 100◦C for 15 min,
then centrifuge at 5000 × g for 1 min, and discard the sediment.
DNA was re-suspended in miliQ H2O as PCR template or stored
at−20◦C until it was used.
In order to extract DNAs of clinical sputum specimens, 2–
3 volumes of 4% NaOH were added to the sputum specimens.
The mixture was agitated at 140 rpm for 30 min at 37◦C. Then 1
ml completely liquefied mixture were added to a new centrifuge
tube, centrifuged at 13,000 rpm for 10 min, and discarded
supernatant. Added 1 ml normal saline into the sediment,
centrifuged at 13,000 rpm for 10 min, discarded supernatant.
Then followed treatments of culture isolate specimensmentioned
above.
Real-Time PCR
Probes design
Ten dually labeled probes and five pairs of primer were designed
to detect key mutations at 40 positions in four gene regions
associated with RIF and INH resistance and conserved region
distinguished MTC from NTM (Table 1).
Four fluorescence (FAM, HEX, ROX, CY5/TAMRA) were
labeled at the 5′end of probes to simultaneously detected in a
single PCR reaction (Figure 1).
We determined the probe coverage according to the position
and frequency of the key drug resistant mutations described in
TB Drug Resistant Mutation Database (https://tbdreamdb.ki.se/
Info/) and our own sequencing results. Specifically, probe rpoB-
TW-A covers mutations in rpoB codon 509–514, probe rpoB-
TW-B in condon 515–520; probe rpoB-TW-C in condon520–
524; probe rpoB-TW-D in condon 524–529; probe rpoB-TW-
E in condon 529–533. And probe katG-TW covers mutations
at katG condon315; probe inhA –TW for mutation at −15
position in mabA-inhA promoter region; probe ahpC-TW-A for
mutations from −2 to −20 positions in intergenic region of
oxyR-ahpC, probe ahpC-TW-B for mutations from −28 to −47
positions in intergenic region of oxyR-ahpC. In addition, probe
rrs -TW was designed to distinguish MTC from NTM, according
to rrs sequence of Mycobacterium strains in the NCBI database
(Table 1, Figure S1).
Three PCR reactions were required to diagnose samples’ RIF
and INH resistance. PCR mixture contained: 10 × PCR buffer
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TABLE 1 | Primers and Probes designed and used in this study.
Primer Target Reationa Conc (µM) Sequence(5′-3′) Product size (bp)
REAL-TIME PCR PRIMERS
rpoB-FP rpoB A,B 0.6 GGTCGCCGCGATCAAGGA 130
rpoB-RP A,B 0.6 CTCACGTGACAGACCGCCG
katG-FP katG B 0.3 GATGGGCTTGGGCTGGAA 131
katG-RP B 0.3 AGCCGTACAGGATCTCGAGGAA
inhA-FP promoter of mabA-inhA B 0.3 GGAAATCGCAGCCACGTTAC 96
inhA-RP B 0.3 TTCAGTGGCTGTGGCAGTCA
rrs-FP 16S rRNA B 0.3 CCTTCGGGTTGTAAACCTCTTTC 132
rrs-RP B 0.3 GGACAACGCTCGCACCC
ahpC-FP intergenic region of oxyR-ahpC C 0.3 CGGCGATGCCGATAAATATG 101
ahpC-RP C 0.3 TCATCAAAGCGGACAATGCA
SEQUENCING PRIMERS
rpoB-CFP rpoB 0.5 CGACGACATCGACCACTTC 501
rpoB-CRP 0.5 GGCGGTCAGGTACACGAT
katG-CFP katG 0.5 GGCGATGAGCGTTACAGC 670
katG-CRP 0.5 CCAAGGTATCTCGCAACGG
inhA-CFP promoter of mabA-inhA 0.5 CCTCGCTGCCCAGAAAGGGA 248
inhA-CRP 0.5 ATCCCCCGGTTTCCTCCGGT
ahpC-CFP intergenic region of oxyR-ahpC 0.5 GACCGGCTTCCGACCA 472
ahpC-CRP intergenic region of oxyR-ahpC 0.5 AACTCGTCATTGAGCTTGCTG
Probe Targeta Reationb Conc(µM) Sequence(5′–3′) 5′Fluorescence Detective 3′Quenching
dye wavelength (nm) dye
rpoB-TW-A rpoB 509–514 A 0.2 GAATTGGCTCAGCTGGCTG CY5 667 BHQ3
rpoB-TW-B rpoB 515–520 A 0.1 ATGGACCAGAACAACCCG ROX 602 BHQ2
rpoB-TW-C rpoB 520–524 B 0.3 GTCAACCCCGACAGCGG CY5 667 BHQ3
rpoB-TW-D rpoB 524–529 A 0.6 GTTGACCCACAAGCGCCG HEX 556 eclipse
rpoB-TW-E rpoB 529–533 A 0.6 CAGCGCCGACAGTCG FAM 520 eclipse
katG-TW katG 313–318 B 0.1 ATCACCAGCGGCATCG FAM 520 eclipse
inhA-TW mabA-inhA −8∼–24 B 0.1 GCGGCGAGACGATAGGT ROX 602 BHQ2
ahpC-TW-A oxyR-ahpC −2∼–20 C 0.3 CTTCACGGCACGATGGAAT CY5 667 BHQ3
ahpC-TW-B oxyR-ahpC −28∼–49 C 0.3 TGTGATATATCACCTTTGCCTG HEX 556 eclipse
rrs-TW rrs(16S rRNA) B 0.6 AGGTCCGGGTTCTCTCGGATT HEX 556 eclipse
aNegative numbers in designations indicate positions of mutations located before the start codon of the gene.
bA, B, and C, the three multi-fluorescence real-time PCR reactions.
2 µl, dNTP (each 2.5 µM) 1.6 µl, MgCl2 (25mM) 0.8 µl,
Taq(5U/ul) 0.2 µl, primers, and probes (Optimal concentrations
of primers and probes for each PCR reaction are shown
in Table 1), extracted DNA template 1 µl, miliQ H2O was
added to make up the whole PCR mixture volume to 20 µl.
Final concentrations of probes were different, in order to get
the equivalent fluorescence signal level. Cycling parameters
were denatured at 94◦C for 2 min, followed by 40 cycles of
amplification at 95◦C for 15 s, 62◦C for 1 min. A negative control
which ddH2O replace the DNA sample and a positive control
(DNA extraction of H37Rv) were included for each real-time
PCR assay.
Results Analysis
Firstly, when rrs probe signal was negative, template is
determined as NTM, positive signal means MTC. Secondly,
signals of the other nine drug resistant probes were investigated.
Positive signals of all the five RIF probes (rpoB-TW-A ∼rpoB-
TW-E) represented no mutation in the 81 bp core region of rpoB,
meaning that this sample was RIF-sensitive, otherwise means
the sample is RIF-resistant. Similarly, the sample was INH-
sensitive when probes katG-TW, inhA-TW, ahpC-TW-A, and
ahpC-TW-B were all positive. Otherwise means INH-resistant
(Table S1).
Analytical Sensitivity and Specificity
Reactions were performed with serially diluted genomic
DNAs (gDNA; range, 5.0 × 105–5.0 × 100 copies per
reaction mixture) of H37Rv. Concentration of each gDNA
was determined by an SMA1000 UV spectrophotometer
(Merintion, CN).
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FIGURE 1 | Analysis of DNAs from Mycobacteria with 10 TaqMan probes by multi-fluorescence real-time PCR. (A) Results of reation I (B) Results of reation
II (C) Results of reation III.
Frontiers in Microbiology | www.frontiersin.org 4 April 2016 | Volume 7 | Article 618
Peng et al. Real-Time PCR Detect M. tuberculosis
In order to investigate the specificity of MF-qRT-PCR, DNAs
extract fromH37Rv,BCG,E.coli, clinical strains ofM. tuberculosis,
M. bovis, and NTM were used as real time - PCR template.
Statistical Analysis
Data was categorized usingMicrosoft EXCEL 2010 and processed
using the SPSS software package, version 19.0. Specificity,
sensitivity, positive and negative predictive values and 95%
confidential interval (CI) of MF-qRT-PCR assay were calculated
with Graph Pad Prism 6.
Sequencing
Following fragments were amplified and sequenced: 501 bp
segment of rpoB, 670 bp of katG, 248 bp of inhA promoter
region, 472 of intergenic region of oxyR-ahpC. Sequencing
primer sequences were presented in Table 1. PCR conditions
were denaturation at 94◦C for 10 min, followed by 35 cycles
of amplification at 94◦C for 30 s, 60◦C for 30 s, 72◦C for 30 s.
Primers were synthesized by JieLi Bio Co. (China). PCRmixtures
were prepared using 2 × GoldStar Best MasterMix (CWBio Co.,
China). Sequence data were assembled and analyzed by BioEdit
software.
Drug Susceptibility Testing (DST)
Proportion method was performed on DSTs use the following
drug concentrations in themodified Löwenstein-Jensenmedium:
RIF, 40.0 µg/ml; INH, 0.2 µg/ml (Zhang et al., 2007).
Identification of Isolates
261MTC and NTM discrimination Culture isolates fromWuhan
previously identified by conventional biochemical methods were
confirmed by 16S rRNA gene sequencing. Strains isolates from
Shenzhen and Shanghai were discriminate as MTC or NTM by
Bactec MGIT 960.
RESULTS
Characterization of Clinical Isolates (Strain
Identification and Conventional DST
Results)
A total of 261 isolates were collected (Table 2). Among these,
227 isolates (87.0%) were MTC, 34 (13.0%) isolates were NTM.
Among MTC, Phenotypic DST showed that 50 (22.0%) were
pan-susceptible and177 (78.0%) resistant to at least one drug.
Specifically, 14 isolates (6.17%) were only resistant to rifampin
and 29 isolates (12.8%) merely to isoniazid, and combined
resistance to both drugs (MDR-TB) was recorded in 134 strains
(59.0%).
Identification of Mutations in Clinical
Isolates (Sequencing Results)
Table S2 shows detailed information about the mutations that
detected in rpoB 81-bp core region. Altogether, 63.4% (144/227
isolates) of the MTC isolates, or 97.3% (144/148 isolates) of the
RIF-resistant isolates, harbored mutations in 14 codons of the
81-bp core region of rpoB. The most frequently mutated rpoB
codons were codons 531, 526, 516, 511, and 533 with mutation
frequencies of 53.5, 20.8, 13.2, 3.47, and 3.47%, respectively.
These five mutations can emerge independently. No mutations
in rpoB were detected in the 79 RIF-sensitive isolates.
A total of 63.0% (143/227) of MTC, or 87.7% (143/163) of
INH-resistant strains had mutations in one or more of three
regions (Table S3). The most frequent mutation site was katG315;
90.0% (99/110). 15.1% (25/166) of the INH-resistant strains
harbored mutations in the promoter region of mabA-inhA.
Most of the mutations appear at −15 positon with a ratio of
84% (21/25). 16.3% (27/166) of the INH-resistant strains had
mutations in intergenic region of oxyR-ahpC. Most mutations
in these region scattered at ahpC-6, ahpC-9, ahpC-10,ahpC-
12,ahpC-17,ahpC-32, and ahpC-39 with similar ratio.
Taken together, mutations in the 81-bp core region of
rpoB and mutation sites in three isoniazid resistance-conferring
regions identified 97.3% of the RIF-resistant isolates and 87.7% of
the INH-resistant isolates.
Assess Sensitivity and Specificity of
MF-qRT-PCR
Serial dilutions of M. tuberculosis H37Rv DNA were detected
employing MF-qRT-PCR. Results revealed the sensitivity of this
assay. For rrs-TW probe, 5.0 × 100 copies/reaction of H37Rv
DNA could be identified effectively (Figure S2).
Signals of 16S rRNA probes were negative, when H2O, DNAs
extracted from clinical strains of NTM as well as E. coli were used
as real time—PCR template. On the other hand, we got positive
results of 16S rRNA signals when detectingH37Rv, clinical strains
of M. tuberculosis, M. bovis, and BCG. Therefore, specificity of
this method for theM. tuberculosis complex was quite prominent.
qRT-PCR Evaluation of MF-qRT-PCR Assay
Two hundred and twenty seven DNAs extractions of MTC
were analyzed using DST, DNA sequencing, and MF-qRT-PCR.
Compared to Phenotypic DST results, for RIF-resistance, the
sensitivity of MF-qRT-PCR was 94.6% (91.0–98.2%), specificity
was 100.0%, positive predictive value was 100.0%, negative
predictive value was 90.8%(84.7–96.9%). For INH-resistance, the
sensitivity was 85.9% (80.6–91.2%), specificity was 95.3% (90.1–
100.0%), positive predictive value was 97.9% (95.6–100.0%),
negative predictive value was 72.6% (63.1–82.2%) (Table 3).
Compared to DNA sequencing results, for RIF-resistance, the
sensitivity was 97.2% (94.5–99.9%), specificity was 100.0%,
positive predictive value was 100.0%, negative predictive value
was 95.4%(91.0–99.8%). For INH-resistance, the sensitivity
was 97.9% (95.6–100.0%), specificity was 96.4% (92.5–100.0%),
positive predictive value was 97.9% (95.6–100.0%), negative
predictive value was 96.4% (92.5–100.0%) (Table 3).It suggested
that the results of MF-qRT-PCR were quite consistent with
the other two “gold standard” methods, especially for DNA
sequencing.
MF-qRT-PCR results of several typical mutants were shown
in Figure 1. Figure 1 showed when the probes of MF-qRT-PCR
assay detected their target DNA segments (wild type, with no
typical mutants), apparent fluorescence signals were released,
and “S” shape amplification curves of PCR appeared. When the
probes detected target DNA segments (with at less one mismatch
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TABLE 2 | Locality, species, and drug resistance (detected by three methods) of samples in this study.
A B
Species
Cities
SZa WHb SHc SUM
Drug resistance
Methods
DSTf Sequencing Multi-fluorescence real-time PCR
MTCd 76 131 20 227 pan-sensitive 50 65 65
NTMe 15 19 0 34 SDRg(RIF-resistant) 14 19 19
SUM 91 150 20 261 SDR (INH-resistant) 29 18 22
MDRh 134 125 121
SUM 227 227 227
aSZ, Shenzhen; bWH,Wuhan; cSH, Shanghai; dMTC, Mycobacterium tuberculosis Complex; eNTM, Non-tuberculous Mycobacteria; fDST, drug susceptibility testing; gSDR, Single-drug
Resistant; hMDR, Multi-drug Resistant.
TABLE 3 | Sensitivities and specificities of multi-fluorescence real-time PCR compared to DST and DNA-sequencing results.
Group DST results Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Resistant Susceptible
RIF
Mutant 140 0 94.6 100.0 100.0 90.8
Wild type 8 79
INH
Mutant 140 3 85.9 95.3 97.9 72.6
Wild type 23 61
Group DNA-sequencing results Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Resistant Susceptible
RIF
Mutant 140 0 97.2 100.0 100.0 95.4
Wild type 4 83
INH
Mutant 140 3 97.9 96.4 97.9 96.4
Wild type 3 81
base), no significant signal would be released, and amplification
curves would be flat. It means that the probes of MF-qRT-PCR
assay can distinguish typical mutants in regions of rpoB, katG,
mabA-inhA, oxyR-ahpC, and rrs from wild types very easily and
clearly.
Additional 34 NTM isolates were analyzed along with the 227
MTC isolates. MF-qRT-PCR can distinguish the NTM isolates
from MTC isolates with 100% accuracy rate.
Clinical sputum sample cultured, quantitative PCR and MF-
qRT-PCR assay results all showed that 16 sputum specimens were
TB positive and 17 were TB negative. All 16 TB positive sputum
specimens were RIF and INH sensitive using MF-qRT-PCR assay
and sequencing.
DISCUSSION
Drug-Resistant Mutation
Molecular mechanism of resistance to anti-TB drugs is becoming
clearer. Several studies have demonstrated that 90–95% of
isolates with rifampin resistance have mutations within the
81-bp core region (codons 508–533) of rpoB, (Alcaide and
Telenti, 1997), with emphasis on the codons 516, 526, and
531(Escalante et al., 1998),or codons 531, 526, 516, 533, 513
were the most emerged mutations(Luo et al., 2010). Mutations
at codon 315 of katG, −15 position of the promoter of mabA-
inhA and −6 ∼ −47 positions of intergenic region of oxyR-
ahpC are considered to be responsible for 80–90% of strains
resistant to INH (Cockerill et al., 1995; Slayden and Barry, 2000).
Presence of these mutations indicates RIF and INH resistance.
Our sequencing result approved these conclusions. Mutations in
rpoB 3 isoniazid resistance-conferring regions identified 97.3% of
the RIF-resistant isolates and 87.7% of the INH-resistant isolates.
Molecular DST Methods of TB
Various genotypic molecular methods, especially nucleic acid–
amplification technologies, arose in recent years(García de
Viedma, 2003; Cuevas-Córdoba and Zenteno-Cuevas, 2010;
Abebe et al., 2011), which included conventional sequencing
(Martin et al., 2006), pyrosequencing (Jureen et al., 2006),
high-resolution thermal melt analysis (Hoek et al., 2008; Ramirez
et al., 2010), denaturing gradient gel electrophoresis (DGGE)
(McCammon et al., 2005), solid-phase hybridization-line
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probe assays, INNO-LiPA Rif (Quezada et al., 2007). TB
assay (Innogenetics, Belgium), GenoType MTBDR Plus assay
(HainLifescience, Nehren, Germany) (Brossier et al., 2009),
molecular beacon-based automated platform Xpert MTB/RIF
(Boehme et al., 2010), and digital PCR (Pholwat et al., 2013).Two
main classes of real-time PCR methods had been applied to
detect mutations related to drug-resistance. In the first class,
mutation is detected by melting curve analysis. Three major
assays, fluorescence resonance energy transfer (FRET) probe
melting curve analysis (Saribas et al., 2005), high-resolution
melting curve (HRM) analysis (McCammon et al., 2005;
Pietzka et al., 2009; Ramirez et al., 2010), and probe-based
melting curve analysis technologies(Luo et al., 2011) (including
unlabeled probes, dually labeled probes, and sloppy molecular
beacons), have been applied to detect drug-resistant mutations
in M. tuberculosis. Some commercial diagnostic kits are based
on melting curve analysis including Fluorotype MDRTB(Hain
Lifescience) and Drug-Resistant TB RIF and Drug-Resistant INH
kits(Xiamen Zeesan Biotech). In the second class, fluorescent
signals are generated by hybridization of probes to the target
sequences at the end of each PCR cycle. The fluorogenic
5′exonuclease probe-(TaqMan) (Hillemann et al., 2006), minor
groove binder probe- (MGB) (Wada et al., 2004) and molecular
beacon-based mutation distinguish assays (Banerjee et al.,
2010) belong to this class. Commercial diagnostic kits Xpert
MTB/RIF (Cepheid), RealTime MDR TB (Abbott Molecular),
and BDProbeTecTM (Becton Dickinson) were based on this class
method. Among these methods, the TaqMan probe coupled
with the real-time PCR technology is one of the most accurate,
reliable, and cost-effective nucleic acid–amplification methods.
In this study, we have developed MF-qRT-PCR assay which
used probes with four fluorescent labels for analysis of RIF and
INH resistance, by detecting drug-resistant mutations in the 81-
bp hot-spot region of rpoB, codon 315 of katG, −15 position
in promoter of mabA-inhA, −6 ∼ −47 positions in intergenic
region of oxyR-ahpC. And we can also distinguish MTC from
NTM at the same time by detecting mutations between 451∼471
positions in gene rrs which transcript 16S rRNA.
The Advantage of MF-qRT-PCR
Comparing with the probe based (TaqMan, MGB, molecular
beacon) qRT-PCR method reported before, MF-qRT-PCR had
several advantages.
Firstly, detection ranges of MF-qRT-PCR were wider than
other probes based qRT-PCR before(Torres et al., 2003; Lin et al.,
2004; Yesilkaya et al., 2006; Zenteno-Cuevas et al., 2012). For
RIF-resistance, MF-qRT-PCR detected whole 81 bp core region
in rpoB gene, instead of some mutation in this region. For INH-
resistance, MF-qRT-PCR not only detected mutations in katG
and promoter of mabA-inhA, but also in intergenic region of
oxyR-ahpC. These improvements increased sensitivity of drug
resistance assay, especially for INH-resistance.
Secondly, comparing with (Gomez et al., 2010), data analysis
and result determination of MF-qRT-PCR were easier and
clearer. No need to calculate and compare the CT values between
positive control and negative control, just directly distinguish
positive and negative result by threshold line.
Thirdly, more fluorescence dyes were employed [four-color
instead of single or two-color(Torres et al., 2003; Lin et al., 2004;
Yesilkaya et al., 2006; Gomez et al., 2010; Zenteno-Cuevas et al.,
2012)] in our study. So, MF-qRT-PCR analysis can reduce the
amount of the PCR reactions, decrease the differences between
PCR tubes, and increase the convenience of operation.
Fourthly, the sensitivity and specificity of MF-qRT-PCR
method were equivalent to the 3′-minor groove binder(MGB)
probes-based method(van Doorn et al., 2003; Wada et al., 2004;
Madania et al., 2012) and the cost is about a half of the latter.
When compared to XpertMTB/RIF(Boehme et al., 2010),MF-
qRT-PCR method not only identified rpoB 81 bp core region
of mutation (RIF-resistant) but also detected katG and inhA
(INH- resistance). Instead of the flanking sequence of rpoB
core region that XpertMTB/RIF adapt to, we designed MTC
identification probe targeting the special region within the 16S
rRNA- coding gene (rrs). In this region, the MTC sequences are
highly dissimilar to the sequences of NTM. Therefore, we can
gain drug susceptibility (RIF and INH resistance) results and
distinguish MTC from NTM in a single test. As the genome of
MTC has more copies of 16S rDNA than rpoB, rrs(16S-rDNA)
probe will have higher assay sensitivity than probes targeting
rpoB.
Comparing with melt-curve method (Pietzka et al., 2009;
Ramirez et al., 2010; Luo et al., 2011), MF-qRT-PCR assay had
advantages too.
Firstly, as outlined above, MF-qRT-PCR assay can detect more
genetic loci (such as the intergenic region of oxyR-ahpC) than
previous studies. So the sensitivity of INH-resistance detection
was increased.
Secondly, MF-qRT-PCR assay had easier and clearer result
criteria, because in every mutant position, operator can easily
distinguish “S” shape amplification curves (means wild type, no
mismatch base existed) from flat line (means mutant, at less one
mismatch base existed), as Figure 1 showed, explained in Results
part). In addition, melt-curve method (Pietzka et al., 2009) had to
compare the melting peak temperature between test specimens
and standard wild-type specimens. In another study (Ramirez
et al., 2010), researcher couldn’t distinglish A->T transversion
SNPs from wild type in HRM graph displayed in normalized
mode, so additional amplification curve assay had to be used
to detect Asp516Val in rpoB. That increases the complexity of
analysis.
It was more subjective than the former and requires more
experimental experience to operate, especially when multiple
mutations emerge simultaneously in one reaction or fluorescent
signal is weak.
Finally, the whole testing progress of MT-qRT-PCR can be
finished in 2.5 h. It is faster than conventional DST and most of
the molecular drug-resistance assays.
LIMITATIONS AND IMPROVEMENT
Compare to sequencing result, MF-qRT-PCR got four false
negative cases in detecting RIF resistance (Table 3). We believed
that these four were mixed infected samples (contained both
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wild type and drug-resistant mutant strains). Therefore, wild type
probes used in MF-qRT-PCR can match the wild type templates
in mix type samples, generate significant signals of amplification.
Mutant templates inmix type samples were overshadowed. These
lead to wild type results (false negative cases). At the same time,
three false negative and three false positive cases were found in
detecting INH resistance (Table 3). Cause of three false negative
cases was the sequences of probe inhA-TW which targeted
to mabA-inhA −8 ∼−24 positions (Table 1). The three false
negative cases all have mutant at mabA-inhA −8 position which
was at the 3′end of probe inhA-TW. It means mabA-inhA −8
were not in the best position of probe to distinguish SNP (Figure
S1). The reason of these three false positive should be the low
emission efficiency of CY5 labeled probe (ahpC-TW-A) which
gave out weak amplified signal and misjudge wild type ahpC loci
to mutant.
Compared with DST results, MF-qRT-PCR got increased
false negative case (eight in detecting RIF, 23 in detecting INH
resistance) (Table 3). These were because of the existence of
unknown drug resistant loci and mechanisms.
MF-qRT-PCR needs real-time PCR instrument with multi-
waved channel (no less than four channel). Because of the
rapid spreading of advanced real-time PCR instrument in China
resent years, instrument limitations toMF-qRT-PCRwere greatly
relieved.
Our method had difficulty in detecting mixed strains (both
wild type and drug-resistant mutant) directly, such as Xpert
MTB/RIF. All probes we used are wild-type probes, so if wild
type templates andmutant templates were both in the specimens,
test result would be positive, which covered the presence of the
mutant template. However, if we could control the concentration
of the initial template before PCR reaction, the CT value of the
pure wild-type template will be significantly smaller than the mix
infected template. So if we calculated the1Ct between pure wild-
type and test sample, and set an appropriate CUTOFF value, we
could semi-quantitatively distinguish wild-type infection from
mixed infection.
Low number of positive and drug-resistance clinical
specimens and the lack of susceptibility results of these samples
prevented us from drawing conclusions about performance of
MF-qRT-PCR according to clinical specimens. Further studies
are needed to validate MF-qRT-PCR in these specimens.
Sequence of probe inhA-TW need to be optimized to
target to mabA-inhA −4 ∼−20, so that mutant at mabA-
inhA−8,−15,−17 positions can be detected at the same time.
It’s easy to increase a probe that specifically recognizes most
species of Mycobacterium using this approach, so that it can
cooperate with rrs (16S rRNA) probe to distinguish MTC, NTM,
and other bacteria succinctly and accurately. Likewise, probes
targeting other genes or regions associated with other anti-TB
drugs could be added to this assay without technical limitations.
CONCLUSIONS
In summary, we have developed a widely applicable MF-qRT-
PCR assay to detect RIF and INH-resistant mutations in M.
tuberculosis and distinguish MTC from NTM in 2.5 h. This
improved approach has been proven to be efficient, accurate,
reliable, and easy-operated. Further studies are required to
optimize this method and evaluate its performance on clinical
sputum and other types of specimens.
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